Verified peer comparison

BSX vs SYK

Boston Scientific Corporation compared with Stryker Corporation. This page compares both source-verified company profiles and does not introduce an unverified price target.

BSX

Boston Scientific Corporation

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

SYK

Stryker Corporation

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

BSX: Health Care Equipment

SYK: Health Care Equipment

Upside lens

BSX: FARAPULSE adoption can expand electrophysiology procedure share and associated catheter demand. WATCHMAN and related structural-heart platforms can benefit from broader physician adoption and indications. A broad cadence of launches across cardiology, endoscopy and urology can sustain above-market procedure growth.

SYK: Robotic placements can pull through implants, disposables and service revenue while deepening surgeon adoption. Healthy elective procedure volumes can sustain demand across hips, knees, trauma and surgical equipment. New implants, neurovascular tools and operating-room technologies can extend share gains.

Risk lens

BSX: Trial outcomes, approval delays or safety signals can slow adoption of important growth platforms. Acquisitions can create integration costs, leverage and execution demands across a rapidly expanding portfolio. Large rivals and new technologies can pressure pricing, physician loyalty and market share.

SYK: Component shortages, quality issues or sterilization constraints could disrupt high-demand product availability. Budget pressure can delay purchases of robots, beds and other capital equipment. Frequent portfolio additions can raise integration, valuation and management-attention risk.